Equities

StemRIM Inc

4599:TYO

StemRIM Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)453.00
  • Today's Change5.00 / 1.12%
  • Shares traded135.40k
  • 1 Year change-38.03%
  • Beta1.8227
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Jul 31 2024202420232022
ASSETS
Cash And Short Term Investments8,41010,2188,880
Total Receivables, Net------
Total Inventory298.514.35
Prepaid expenses242208270
Other current assets, total1956.59108
Total current assets8,87710,4409,263
Property, plant & equipment, net186227274
Goodwill, net------
Intangibles, net2.440.800.86
Long term investments------
Note receivable - long term------
Other long term assets9.599.599.59
Total assets9,08010,7069,597
LIABILITIES
Accounts payable------
Accrued expenses242230
Notes payable/short-term debt--00
Current portion long-term debt/capital leases--0.533.14
Other current liabilities, total4319539
Total current liabilities6821872
Total long term debt--00.53
Total debt--0.533.67
Deferred income tax9.971012
Minority interest------
Other liabilities, total108108108
Total liabilities186336192
SHAREHOLDERS EQUITY
Common stock111676
Additional paid-in capital9,4239,01210,620
Retained earnings (accumulated deficit)(539)1,343(1292)
Treasury stock - common(0.12)(0.12)(0.03)
Unrealized gain (loss)------
Other equity, total00.00--
Total equity8,89510,3709,405
Total liabilities & shareholders' equity9,08010,7069,597
Total common shares outstanding626159
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.